Labcorp (NYSE:LH – Get Free Report) and bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Institutional and Insider Ownership
95.9% of Labcorp shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Labcorp and bioAffinity Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Labcorp | $13.95 billion | 1.82 | $876.50 million | $12.09 | 25.93 |
| bioAffinity Technologies | $6.16 million | 0.35 | -$14.91 million | ($109.45) | -0.03 |
Labcorp has higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Labcorp and bioAffinity Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Labcorp | 0 | 3 | 9 | 0 | 2.75 |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
Labcorp presently has a consensus target price of $337.73, indicating a potential upside of 7.74%. Given Labcorp’s stronger consensus rating and higher possible upside, equities analysts clearly believe Labcorp is more favorable than bioAffinity Technologies.
Profitability
This table compares Labcorp and bioAffinity Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Labcorp | 6.99% | 16.74% | 7.81% |
| bioAffinity Technologies | -257.30% | -220.52% | -136.76% |
Volatility & Risk
Labcorp has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of -1.25, indicating that its stock price is 225% less volatile than the S&P 500.
Summary
Labcorp beats bioAffinity Technologies on 12 of the 13 factors compared between the two stocks.
About Labcorp
Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
